A Phase I Trial of Concurrent RHUMAB VEGF (BEVACIZUMAB) and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Safety of combination Radiation, Bevacizumab, and Capecitabine.
研究概览
简要总结
The goal of this clinical research study is to find the highest safe dose of the drug Bevacizumab that can be given in combination with chemoradiation for the treatment of pancreatic cancer. The effect that this combination treatment has on the tumor will also be studied.
详细描述
This study administers 50.4 Gy of radiation for unresectable pancreatic cancer with concurrent capecitabine and an experimental drug, Bevacizumab. The drug is an antiangiogenic agent (kills tumor blood vessels) and has been shown in preclinical models to enhance the antitumor effect of radiation and chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Cytology or histologic proof of adenocarcinoma of the pancreatic head, body or tail prior to treatment.
- •Patients with nonmetastatic, unresectable, disease are eligible.
- •Patients with regional nodal disease are eligible.
- •Karnofsky performance status >/=
- •No upper age restriction.
- •Absolute granulocyte count >1,500 cells/mm3 and platelet count at least 100,000 cells/mm
- •Serum bilirubin less than 5mg/dl prior to the start of therapy with adequate biliary decompression.
- •Adequate bilateral renal function.
- •Serum creatinine <1.5 mg/dl.
- •Adequate liver function; Alanine aminotransferase (ALT)/aspartate aminotransferase (AST)</=5 times upper limit of normal.
- •Sexually active men must practice contraception during study.
- •Patients must sign study-specific consent form.
排除标准
- •History or evidence upon physical examination of CNS disease.
- •Active infection requiring parenteral antibiotics on Day
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of the study.
- •Current or recent use of full-dose oral or parenteral anticoagulants or thrombolytic agent.
- •Chronic, daily treatment with aspirin or nonsteroidal anti-inflammatory medications.
- •Pregnancy or lactation.
- •Proteinuria at baseline or impairment of renal function.
- •Serious, nonhealing wound, ulcer, or bone fracture.
- •Evidence of bleeding diathesis or coagulopathy
- •Clinically significant cardiovascular disease, congestive heart failure, serous cardiac arrhythmia requiring medication, or significant peripheral vascular disease within 1 year prior to Day
- •History of aneurysms, strokes, transient ischemic attacks, and arteriovenous malformations.
- •Serous concomitant medical or psychiatric disorders.
- •Cohort receiving Capecitabine
研究组 & 干预措施
Bevacizumab
Radiation, Bevacizumab, and Capecitabine
干预措施: Bevacizumab (Drug)
Bevacizumab
Radiation, Bevacizumab, and Capecitabine
干预措施: Capecitabine (Drug)
Bevacizumab
Radiation, Bevacizumab, and Capecitabine
干预措施: Radiotherapy (Radiation)
结局指标
主要结局
Safety of combination Radiation, Bevacizumab, and Capecitabine.
时间窗: 6 weeks after the completion of therapy
次要结局
- To evaluate tumor hypoxia via PET scanning (gallium PET with the novel hypoxia tracer Ga-68 ECMN) before, during, and after therapy.(6 weeks after the completion of therapy.)
- To evaluate VEGF serum levels before and after anti-VEGF therapy.(6 weeks after the completion of therapy.)
- To evaluate quality of life in patients receiving this therapy.(6 weeks after the completion of therapy.)
- To evaluate the local tumor response and median survival in patients treated with the above regimen.(6 weeks after the completion of therapy.)